Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
Kenichi Tsujita(British Heart Foundation), Hisao Ogawa(Jikei University School of Medicine), Toshiyuki Matsumura(Japan Organization of Occupational Health and Safety), Kenji Sakamoto(Kumamoto University), Kunihiko Matsui(Kumamoto University), Ryusuke Tsunoda(Japanese Red Cross Kumamoto Hospital), Hideki Shimomura(Fukuoka Tokushukai Hospital), Koushi Matsuyama(Omuta hospital), Natsuki Nakamura(Beppu Medical Center), Nobuyasu Yamamoto(Miyazaki Prefectural Hospital), Naritsugu Sakaino, Seiji Hokimoto(Omuta hospital), Masaharu Ishihara(Hyogo Medical University), Seigo Sugiyama(Kumamoto University), Sunao Nakamura(New Tokyo Hospital), Takuro Yamashita(Omuta hospital), Koichi Kaikita(Kumamoto University), Kazuteru Fujimoto(Kumamoto Medical Center), Kōichi Nakao(Saiseikai Kumamoto Hospital), Yasuhiro Morikami(Kumamoto City Hospital), Hideki Oka, Shuichi Oshima(Kumamoto Chuo Hospital), Shunichi Koide(Kumamoto Medical Center), Naohiro Komura(Kumamoto University), Hitoshi Sumida(Kumamoto Chuo Hospital), Kenshi Yamanaga(Kumamoto University)
Cited by 449
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753